ClinicalTrials.gg
RecruitingNCT07489911STRENGTHUpdated Mar 24, 2026

Fixed Triple Inhaled Combination in Asthmatic Patients in a Real-life Setting (STRENGTH)

An observational study in Asthma, Asthma Patients and Asthma Bronchiale, sponsored by Chiesi Slovenija, d.o.o.. Recruiting at 18 sites in Slovenia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-24.

Sponsored by Chiesi Slovenija, d.o.o. (part of Chiesi Farmaceutici S.p.A.) · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Nov 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 81 studies in Asthma by Chiesi Farmaceutici S.p.A. — 11 open to participants now, 11 under way, 2 of them phase 3. Asthma · Chiesi Farmaceutici S.p.A..

Planned enrollment
12th of 15
200 · median 300
Started
2024
with 3 others
Observational
15 of 81
6 open now
Primary completion
2026-07
later than 3 of 10 live
Registered
77th of 81
by date

Among the 81 studies in Asthma by Chiesi Farmaceutici S.p.A., this one is the 12th largest by planned enrollment of the 15 observational ones that give a count, is one of 4 that started in 2024, is one of 15 observational ones, reaches primary completion later than 3 of the 10 other live ones, and was the 77th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

11 of the 81 studies in Asthma by Chiesi Farmaceutici S.p.A. are open now, in 12 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Who these studies take

Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in Asthma by Chiesi Farmaceutici S.p.A., or all of them as a file.
02

Study summary

The mainstay of asthma treatment are ICSs, mostly combined with LABA. In the past decade LAMA had been accepted as an add-on treatment for patients at GINA steps 4 and 5. Recently, RCTs proved the efficacy and safety of fixed triple combinations of moderate and high dose of ICS and LABA, LAMA in a very selected asthmatic population, resulting in the market authorisation of these products. However, there is a lack of evidence on the real-world effectiveness of these therapies, especially with regards to improvement in symptom scores and adherence.

Read the detailed description

Study design Multicentre, national, non-interventional, prospective study evaluating the effectiveness of Trimbow 172/5/9 μg pMDI on symptom scores in 6 months after switch from previous LABA-high dose ICS containing treatment in asthmatics.

Dosage regimen and administration Name of the product: Trimbow 172 micrograms/5 micrograms/9 micrograms pressurised inhalation, solution (henceforth abbreviated as Trimbow 172/5/9 µg pMDI) . Each delivered dose (the dose leaving the mouthpiece) contains 172 µg of beclometasone dipropionate, 5 µg of formoterol fumarate dihydrate and 9 µg of glycopyrronium (as 11 µg glycopyrronium bromide). Each metered dose (the dose leaving the valve) contains 200 µg of beclometasone dipropionate, 6 µg of formoterol fumarate dihydrate and 10 µg of glycopyrronium (as 12.5 µg glycopyrronium bromide). The recommended dose is two inhalations twice daily. The maximum dose is two inhalations twice daily.

  1. AIM OF THE STUDY (research objective)

    Primary objective:

    The main objective is to assess the effectiveness of BDP/FF/G 172/5/9 μg fixed triple combination in a real-world setting, with regards to improvements in symptom scores (ACT).

    Primary outcome measures:

    • Change (improvement) of ACT score, during the 6 months of treatment (Visit 3), compared to the score at baseline.
    • The percentage of patients achieving an improvement in ACT score of 3 points (MCID, minimum clinically important difference) or more, after the 6 months treatment (Visit 3) compared to baseline.

    Secondary objectives:

    Secondary objectives are the assessments of improvement in lung function and adherence to treatment.

  2. TEST SAMPLE AND METHOD, RECRUITMENT PRINCIPLE No patient recruitment will be performed. Eligible patients will be enrolled during their regular asthma management with participating physicians after giving their written informed consent. Patient inclusion will take place among patients having severe asthma and attending pulmonology outpatient clinics (the chosen study sites are attached as annexes to the study protocol), strictly at the time of the patient's visit. The planned number of patients is 200.
  3. STRUCTURE OF THE STUDY In accordance with the requirements of non-interventional studies, the assignment of patients to Trimbow 172/5/9 μg pMDI therapy should be made independently of the study, and patients should only be considered for inclusion in the study after a prior therapeutic decision has been made by a pulmonologist. Patient enrolment can take place after the patient has been fully informed about the purpose of the study and all of its details, and the patient has read and signed the patient information leaflet and patient consent form, including any questions they may have. Once this has taken place, the data that would have been generated anyway during the outpatient examination of the patient in accordance with daily practice can be recorded. This is considered the first visit of the study (Visit 1). During this visit, the patient's main demographic data, information on comorbidities and concomitant medications, previous and current asthma therapies, asthma specific assessment (including ACT), exacerbation history, post-dose lung function values (if spirometry data is available), laboratory results (if a laboratory test is performed), maintenance and reliever inhaled therapies (former and new), and adherence to therapy based on Test of Adherence to Inhalers (TAI-12) questionnaire are recorded. Patients will then attend two additional visits 30 days and 6 months after enrolment as per routine clinical practice (Visits 2 and 3). During these visits, data will also be recorded, once again, according to routine clinical practice.

    If the patient's maintenance therapy changes during the study as decided by the treating pulmonologist, and the patient is no longer receiving Trimbow 172/5/9 μg pMDI, the patient will be automatically excluded from this NIS. The fact of the therapy modification and its exact date must be recorded on the "current medication" form in the eCRF (electronic Case Report Form) of the next visit. If the change in therapy is related to a suspected adverse reaction, it should be reported separately on the eCRF platform in accordance with respective section of this protocol.

    This NIS is open to all eligible patients according to the inclusion and exclusion criteria. Permitted concomitant treatments: allowed all medications according to local clinical practice (any non-inhalation therapy for asthma or other diseases) and reliever (short-acting bronchodilators) inhaled therapies for asthma.

  4. START AND DURATION OF THE STUDY The first patient enrolment will take place after receiving approval from the Agency for Medicinal Products and Medical Devices of the Republic of Slovenia, based on a beneficial assessment of the National Medical Ethics Committee of the Republic of Slovenia. The study is planned to start in November 2024. Accordingly, first patient first visit (FPFV) is also planned to take place in November, 2024. Study sites will have 12 months to enrol patients. After the last visit of the last patient (LPLV), centres will have one month to collect all missing data / correct any data flagged as queries during monitoring. The LPLV is expected to take place in June 2026.
  5. STUDY PLAN A total of 3 visits will be performed for the assessment of the primary and secondary endpoints during the study. Patient may be enrolled in the study and their data may only be recorded, if these data would also have been recorded in accordance with standard medical practice.

    • Visit 1: Time of enrolment - a normal visit, according to routine clinical practice. Informed consent and baseline patient characteristics will be collected.
    • Visit 2: 1 month after enrolment (± 2-3 days)
    • Visit 3: 6 months after enrolment (± 5-7 days)
03

Conditions studied

  • Asthma
  • Asthma Patients
  • Asthma Bronchiale

Browse trials for

Keywords

  • Single Inhaler Triple Therapy
  • Asthma
  • SITT
  • Trimbow
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Asthma patients treated at GINA step 5, uncontrolled/ partially controlled with ICS+LABA, containing high dose ICS.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Physician-confirmed clinical diagnosis of asthma according to GINA guidelines and treated for at least 3 years before inclusion
  • Patients ≥ 18 years of age in ambulatory care
  • Uncontrolled asthma according to the physician's clinical assessment despite the use of:

    1. LABA and high dose ICS or
    2. LABA and high-dose ICS + LAMA multi-inhaler triple therapy for a minimum of three months.
  • Patients who are eligible for the use of Trimbow 172/5/9 μg pMDI according to the SmPC :

    1. at least on exacerbation, requiring systemic (oral or intravenous) in the previous 12 months
    2. uncontrolled asthma (ACT≤15) or partially controlled asthma (15\<ACT\<20)
    3. \<80% at baseline
  • Inhaled asthma therapy was changed to Trimbow 172/5/9 μg pMDI no more than 1 week prior to OR on the day of study inclusion
  • Patient provided written, to study participation

Exclusion criteria

EXCLUSION CRITERIA:

  • Participation in any clinical trial within 30 days prior to enrolment
  • Patients hospitalized due to an exacerbation of their asthma within the last 4 weeks prior to enrolment
  • Another respiratory condition, apart from asthma or , that may interfere with the effectiveness of the treatment studied AND/OR another important clinical situation that may interfere with patient's compliance with the treatment.
  • Continuous use of oral (>5 mg prednisolone/day OR >4 mg methylprednisolone/day) OR intravenous
  • Use of continuous oxygen therapy
  • Any malignant disease in the last 5 years
  • Tuberculosis (active or anamnestic)
  • Actual or previous use of biologics for asthma treatment in the past 12 months
  • All exclusion criteria listed in Trimbow 172/5/9 μg pMDI SmPC
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No

Groups and cohorts

  • Asthmatic patients switched to Trimbow (BDP/FF/G 172/5/9 μg)

    Drug: BDP/FF/G (beclometasone dipropionate/formoterol fumarate dihydrate/glycopyrronium) 172/5/9 μg

Interventions

  • DrugBDP/FF/G (beclometasone dipropionate/formoterol fumarate dihydrate/glycopyrronium) 172/5/9 μg

    extrafine SITT

    Also known as: Trimbow 172/5/9 mcg

06

What researchers measure

Primary outcomes

  1. Asthma Control Test

    Change (improvement) of asthma control test (ACT) score, during the 6 months of treatment (Visit 3), compared to the score at baseline.

    Time frame: 6 months

  2. Asthma Control Test 2

    The percentage of patients achieving an improvement in asthma control test (ACT) score of 3 points (MCID, minimum clinically important difference) or more, after the 6 months treatment (Visit 3) compared to baseline.

    Time frame: 6 months

Secondary outcomes

  1. Asthma Control Test Change

    The percentage of patients achieving an improvement according to asthma control levels (uncontrolled= ACT ≤15; partially controlled= 15\<ACT\<20; controlled 20≤ACT)

    Time frame: 6 months

  2. Test of Adherence to Inhalers (TAI)

    Change in Test of Adherence to Inhalers® (TAI-12) score at Visit 3 (6 months) compared to baseline visit (Visit 1, week 0) regarding adherence to treatment with use of the Trimbow 172/5/9 μg pMDI.

    Time frame: 6 months

  3. Lung Function

    Change in spirometric parameters: FEV1, FVC, FEV1/FVC, at Visit 3 (6 months), compared to the baseline Visit 1 (Week 0), with use of the Trimbow 172/5/9 μg pMDI.

    Time frame: 6 months

07

Study locations

18 of 18 sites recruiting
  • AMBULANTA ARIA, specialistična ambulanta za alergijske in pljučne bolezni, d.o.o.
    Celje, 3000, Slovenia
    Recruiting
  • Dr. ŠEGOTA - PULMOLOG, specialistične zdravstvene storitve, d.o.o.
    Celje, 3000, Slovenia
    Recruiting
  • Internistična Ambulanta Za Pljučne in Alergijske Bolezni - Karmen Kramer Vrščaj Dr. Med.
    Celje, 3000, Slovenia
    Recruiting
  • MEDICOINTERNA, medicinske storitve in svetovanje, d.o.o.
    Kočevje, 1330, Slovenia
    Recruiting
  • Zdravstveni Dom Koper Casa Della Sanita Capodistria
    Koper, 6000, Slovenia
    Recruiting
  • VELOG Zdravstveni center d.o.o.
    Kranj, Slovenia
    Recruiting
  • ARJANA MAČEK, zdravstvene in druge storitve, d.o.o
    Ljubljana, 1000, Slovenia
    Recruiting
  • KAMBIČ - KAFOL, medicinsko svetovanje in storitve, d.o.o.
    Ljubljana, 1000, Slovenia
    Recruiting
  • MEDI PULMO, interna medicina, d.o.o.
    Ljubljana, 1000, Slovenia
    Recruiting
  • OBJEM ZDRAVJA zdravstveno svetovalni center d.o.o.
    Ljubljana, 1000, Slovenia
    Recruiting
  • PULMEDICO, specialistična zdravstvena dejavnost, d.o.o.
    Ljubljana, 1000, Slovenia
    Recruiting
  • ALVEOLA internistični ambulantni diagnostični center d.o.o.
    Maribor, 2000, Slovenia
    Recruiting
  • Zasebna Ambulanta Za Pljučne Bolezni, Mag. Alojz Horvat, Dr. Med. Specialist Interne Medicine
    Murska Sobota, 9000, Slovenia
    Recruiting
  • EUPNEA d.o.o.
    Murska Sobota, Slovenia
    Recruiting
  • Zasebna Internistično-Pulmološka Ambulanta, Jasmina Panjan Avramovič, Dr.Med.Spec.
    Portorož, 6320, Slovenia
    Recruiting
  • DLAN, pomoč in nega na domu, specialistična zdravstvena dejavnost, Lucija Gabršček Parežnik s.p.
    Šentjur pri Celju, 3230, Slovenia
    Recruiting
  • Zdravstveni Dom Tolmin
    Tolmin, 5220, Slovenia
    Recruiting
  • Zdravstveni Zavod Pulmoradix Velenje
    Velenje, 3320, Slovenia
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — IDP is sole property of the sponsor and will only be eligible upon reasonable request.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Jul 2026, 20 months after the start.

Of 90 industry-sponsored observational studies under Asthma, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 58. This study's planned 20 months is below that.

Counting every sponsor, half of 456 studies reached it within 36 months; a quarter within 18 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2026
First posted
Mar 24, 2026
StartActual
Nov 4, 2024
Primary completionEst.
Jul 2026
CompletionEst.
Jul 2026
Last update
Mar 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07489911
Responsible party
Sponsor
First posted
Mar 24, 2026
Start date
Nov 4, 2024
Primary completion
Jul 2026 (estimated)
Completion
Jul 2026 (estimated)
Last update
Mar 24, 2026

Study contacts

Mojca Pernek Miložič, MPharm
Contact
m.pernek@chiesi.com
+38640292828
Marina Štrucelj, MPharm
Contact
m.strucelj@chiesi.com
0038640177210

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion